Elizabeth Cartwright Pfaffenroth1, W Marston Linehan. 1. National Cancer Institute, Medical Oncology, Urologic Oncology Branch, 10 Center Drive MSC 1107, Building 10 CRC Room 1-5942, Bethesda, Maryland 20892-1107, USA. pfaffee@mail.nih.gov
Abstract
BACKGROUND: Kidney cancer is not a homogenous entity; it is comprised of many different tumor types, with different biologies and molecular mechanisms leading to disease and therefore different treatment approaches. OBJECTIVE: To describe the genetic basis and biochemical pathways underlying inherited forms of renal cancer, specifically in four described syndromes (von Hippel-Lindau [VHL], hereditary papillary renal cancer [HPRC], Birt-Hogg-Dubé [BHD] and hereditary leiomyomatosis renal cell carcinoma [HLRCC]), and to elucidate how the understanding of these diseases enables the possibility of disease-specific approaches to therapy. METHODS: A systematic review of the published literature on inherited and sporadic forms of renal cancer was performed. CONCLUSION: Understanding of the biology and mechanisms of different forms of kidney cancer provides an opportunity for development of new treatment options.
BACKGROUND:Kidney cancer is not a homogenous entity; it is comprised of many different tumor types, with different biologies and molecular mechanisms leading to disease and therefore different treatment approaches. OBJECTIVE: To describe the genetic basis and biochemical pathways underlying inherited forms of renal cancer, specifically in four described syndromes (von Hippel-Lindau [VHL], hereditary papillary renal cancer [HPRC], Birt-Hogg-Dubé [BHD] and hereditary leiomyomatosis renal cell carcinoma [HLRCC]), and to elucidate how the understanding of these diseases enables the possibility of disease-specific approaches to therapy. METHODS: A systematic review of the published literature on inherited and sporadic forms of renal cancer was performed. CONCLUSION: Understanding of the biology and mechanisms of different forms of kidney cancer provides an opportunity for development of new treatment options.
Authors: T Shuin; K Kondo; S Torigoe; T Kishida; Y Kubota; M Hosaka; Y Nagashima; H Kitamura; F Latif; B Zbar Journal: Cancer Res Date: 1994-06-01 Impact factor: 12.701
Authors: F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil Journal: Science Date: 1993-05-28 Impact factor: 47.728
Authors: J G Herman; F Latif; Y Weng; M I Lerman; B Zbar; S Liu; D Samid; D S Duan; J R Gnarra; W M Linehan Journal: Proc Natl Acad Sci U S A Date: 1994-10-11 Impact factor: 11.205
Authors: E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton Journal: J Med Genet Date: 1991-07 Impact factor: 6.318
Authors: Sarah M Nielsen; Wendy S Rubinstein; Darcy L Thull; Michaele J Armstrong; Eleanor Feingold; Linwah Yip; Samuel A Tisherman; Sally E Carty Journal: Fam Cancer Date: 2011-12 Impact factor: 2.375
Authors: W Marston Linehan; Gennady Bratslavsky; Peter A Pinto; Laura S Schmidt; Len Neckers; Donald P Bottaro; Ramaprasad Srinivasan Journal: Annu Rev Med Date: 2010 Impact factor: 13.739